Dr. Erika P. Hamilton on ONT-380 for HER2+ Breast Cancer

Erika P. Hamilton, MD
Published: Thursday, Feb 25, 2016



Erika P. Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program; Principal Investigator, Sarah Cannon Research Institute, discusses ONT-380, a novel HER2-specific inhibitor. Most oral HER2-inhibitors block not only HER2, but other proteins such as EGFR.

These additional proteins can cause toxicities such as rash and diarrhea, says Hamilton. ONT-380 only blocks the HER2, so it tends to be more tolerable, she says. It also crosses the blood-brain barrier. This is important because up to 50% of HER2-positive breast cancer patients experience brain metastasis.


Erika P. Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program; Principal Investigator, Sarah Cannon Research Institute, discusses ONT-380, a novel HER2-specific inhibitor. Most oral HER2-inhibitors block not only HER2, but other proteins such as EGFR.

These additional proteins can cause toxicities such as rash and diarrhea, says Hamilton. ONT-380 only blocks the HER2, so it tends to be more tolerable, she says. It also crosses the blood-brain barrier. This is important because up to 50% of HER2-positive breast cancer patients experience brain metastasis.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x